Skip to main content
. 2022 Jul 6;10(7):e004848. doi: 10.1136/jitc-2022-004848

Figure 2.

Figure 2

Potential clinical interest of imaging biomarkers for radiotherapy-immunotherapy combinations. Lesion-level analyses may help to identify potential immune-refractory lesions (high-risk lesions) needing focal destruction with ablative SBRT (high dose RT) or immunogenic lesions for which low dose RT may improve systemic response. Patient-level analyses allow overall response prediction. RT, radiotherapy; SBRT, stereotactic body radiation therapy.